Form 4: Cytek Biosciences CTO Reports Stock Transaction
Insider Transaction (Form 4)
Ming Yan, CHIEF TECHNOLOGY OFFICER and a Director of Cytek Biosciences, Inc., reported multiple transactions in common stock on August 18, 2026.
Summary
- Option exercise/conversion: acquired 7,363 Common Stock on August 18, 2026; holds 4,804,051 after (Direct).
- Tax/exercise-price withholding: disposed of 1,778 Common Stock at $4.67 ($8,303) on August 18, 2026; holds 4,802,273 after (Direct).
- Option exercise/conversion: acquired 5,525 Common Stock on August 18, 2026; holds 4,807,798 after (Direct).
- Tax/exercise-price withholding: disposed of 1,346 Common Stock at $4.67 ($6,286) on August 18, 2026; holds 4,806,452 after (Direct).
- Option exercise/conversion: acquired 6,162 Common Stock on August 18, 2026; holds 4,812,614 after (Direct).
- Tax/exercise-price withholding: disposed of 1,501 Common Stock at $4.67 ($7,010) on August 18, 2026; holds 4,811,113 after (Direct).
- Option exercise/conversion: acquired 14,220 Common Stock on August 18, 2026; holds 4,825,333 after (Direct).
- Tax/exercise-price withholding: disposed of 3,463 Common Stock at $4.67 ($16,172) on August 18, 2026; holds 4,821,870 after (Direct).
- Option exercise/conversion: disposed of 7,363 Restricted Stock Units on August 18, 2026; holds 17,189 after (Direct).
- Option exercise/conversion: disposed of 5,525 Restricted Stock Units on August 18, 2026; holds 34,995 after (Direct).
- Option exercise/conversion: disposed of 6,162 Restricted Stock Units on August 18, 2026; holds 63,688 after (Direct).
- Option exercise/conversion: disposed of 14,220 Restricted Stock Units on August 18, 2026; holds 203,835 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ming Yan — Director, Officer (CHIEF TECHNOLOGY OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Option exercise/conversion | Common Stock | 7,363 | — | — | 4,804,051 |
| 2026-08-18 | Tax/exercise-price withholding | Common Stock | 1,778 | $5 | $8.3K | 4,802,273 |
| 2026-08-18 | Option exercise/conversion | Common Stock | 5,525 | — | — | 4,807,798 |
| 2026-08-18 | Tax/exercise-price withholding | Common Stock | 1,346 | $5 | $6.3K | 4,806,452 |
| 2026-08-18 | Option exercise/conversion | Common Stock | 6,162 | — | — | 4,812,614 |
| 2026-08-18 | Tax/exercise-price withholding | Common Stock | 1,501 | $5 | $7.0K | 4,811,113 |
| 2026-08-18 | Option exercise/conversion | Common Stock | 14,220 | — | — | 4,825,333 |
| 2026-08-18 | Tax/exercise-price withholding | Common Stock | 3,463 | $5 | $16.2K | 4,821,870 |
| 2026-08-18 | Option exercise/conversion | Restricted Stock Units | 7,363 | — | — | 17,189 |
| 2026-08-18 | Option exercise/conversion | Restricted Stock Units | 5,525 | — | — | 34,995 |
| 2026-08-18 | Option exercise/conversion | Restricted Stock Units | 6,162 | — | — | 63,688 |
| 2026-08-18 | Option exercise/conversion | Restricted Stock Units | 14,220 | — | — | 203,835 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Option exercise/conversion (7,363 shares) |
| 2026-08-18 | Tax/exercise-price withholding (1,778 shares) |
| 2026-08-18 | Option exercise/conversion (5,525 shares) |
| 2026-08-18 | Tax/exercise-price withholding (1,346 shares) |
| 2026-08-18 | Option exercise/conversion (6,162 shares) |
| 2026-08-18 | Tax/exercise-price withholding (1,501 shares) |
| 2026-08-18 | Option exercise/conversion (14,220 shares) |
| 2026-08-18 | Tax/exercise-price withholding (3,463 shares) |
| 2026-08-18 | Option exercise/conversion (7,363 shares) |
| 2026-08-18 | Option exercise/conversion (5,525 shares) |
| 2026-08-18 | Option exercise/conversion (6,162 shares) |
| 2026-08-18 | Option exercise/conversion (14,220 shares) |
Keywords
insider transaction, Form 4, CTKB, Cytek Biosciences, Inc., neutral, Ming Yan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.